WINNIPEG, MANITOBA -- (Marketwire) -- 12/20/12 -- Miraculins Inc. (TSX VENTURE: MOM), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs; London Drugs, one of Canada's leading pharmacy chains; and Pear Healthcare Solutions, a leading provider of in-pharmacy health screening and educational services, today announce that London Drugs will be expanding its offering of the PreVu® Non-Invasive Skin Cholesterol Point of Care (POC) Test to all 76 physical pharmacy locations in more than 35 major markets throughout Western Canada.
"I am pleased to confirm that we will be expanding our PreVu POC Test programming to all of our stores beginning in March 2013," said John Tse, Vice President, Pharmacy for London Drugs. "Based on a very successful pilot at our pharmacy locations in Vancouver and the Lower Mainland, as well as in Winnipeg, and the positive response of the public and our pharmacy team, we see significant value in bringing the PreVu POC Test to customers throughout our entire network of stores, to help them better understand their potential risk of coronary artery disease."
"The Canadian launch of PreVu through London Drugs has established the viability and potential of distributing this revolutionary new screening technology through a retail pharmacy platform," said Paul Moreau, Vice President, Sales and Marketing for Miraculins Inc. "We have been diligent in advancing the business model for the pharmacy market given its enormous consumer reach, and these pilots have allowed us to further refine and prepare the model for duplication. The pioneering vision of London Drugs, further underscored by its decision to expand PreVu to all of its stores, signals the graduation of a test delivery system that can now be replicated in pharmacies across the country and internationally."
Based upon a patient's PreVu test results, formal risk assessment under a healthcare provider's direction, including blood cholesterol testing and global risk assessment, may be warranted, or should be considered. The PreVu POC Test does not diagnose the presence or absence of coronary artery disease (CAD), but without blood draw or fasting it can quickly identify individuals who may possess hidden, higher levels of risk of CAD by measuring their skin cholesterol levels, and encouraging them to see their doctors. Clinical studies have shown that elevated skin cholesterol is strongly associated with an increased risk of serious atherosclerotic disease.(i) PreVu is not a substitute for blood serum cholesterol testing.
Miraculins also recently announced the launch of its French language web site for PreVu for the Canadian marketplace (www.prevu.com) and issued a year-end summary report on PreVu operating, marketing and distribution progress.
(i)PreVu clinical study references can be sourced at www.prevu.com.
About The PreVu® Non-Invasive Skin Cholesterol Test
The PreVu® Point of Care (POC) Test is a non-invasive, risk assessment technology designed to measure Skin Cholesterol - an important new biomarker in assessing risk of coronary artery disease (CAD). The PreVu® POC Test is completely painless, non-invasive, involves no blood draw or needles, and requires no overnight fasting. This in vitro diagnostic test is conducted on the palm of the hand in less than 5 minutes with results being immediately available, facilitating point of care consultation and a next steps discussion. Skin Cholesterol is the cholesterol that has been deposited and diffused into tissue, as opposed to freely circulating in the bloodstream, and the skin contains approximately 11% of all the cholesterol found in the human body. Elevated Skin Cholesterol has been shown in clinical studies to be strongly associated with significant CAD as measured by treadmill stress testing and coronary angiography, as well as measured by testing for coronary calcium, carotid artery thickening, and carotid artery plaque. The PreVu® POC Test does not diagnose the presence or absence of CAD, but helps to identify patients who may be at higher, hidden risk for CAD by measuring this new biomarker. For more information visit www.prevu.com.
Most Popular Stories
- Bipartisan Budget Deal Gets Key Support in House
- Bitcoin Clones Lurch Onto Financial Scene
- Clinton to Keynote Annual Simmons Leadership Conference
- Futures Fall, Holiday Spending and Unemployment Up
- Budget Deal Will Cut 220,000 Californians Out of Jobless Benefits
- Senate Not So Keen on Budget Deal
- Oil Nears $98 a Barrel
- PhD Project Grooms Business Profs
- Selena Gomez, Shakira Among Top Hispanic Searches
- GM to Stop Making Autos in Australia